Clinical Outcome and Cost-effectiveness of Reduced Noradrenaline by Using a Lower Blood Pressure Target in Patients With Cardiogenic Shock From Acute Myocardial Infarction

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 776 participants.

Also called NCT05168462

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 776 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05168462
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Netherlands (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05168462. Randomized; no masking; primary purpose treatment. Start 2022-10-01 (actual); primary completion 2027-04-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Clinical Outcome and Cost-effectiveness of Reduced Noradrenaline by Using a Lower Blood Pressure Target in Patients With Cardiogenic Shock From Acute Myocardial Infarction
Acronym
NORSHOCK
Condition
Cardiogenic Shock
Intervention (Drug)
Reduced noradrenaline use
Lead sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (class: other)

Record details

Record id
cardio:ct-nct05168462
Content hash
fc977ddbc8cf9af5c4f7203db2ea525bc5d76aafac329c8eb4e11ff55f70342b